AVBCC Summit Highlights

At the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021, a panel of experts, moderated by Michael Reff, RPh, MBA, Founder and Executive Director, National Community Oncology Dispensing Association (NCODA), Cazenovia, NY, discussed the current and future state of Medically Integrated Pharmacy (MIP) and the benefits of this approach in oncology.
Oncologic drug pricing is being transformed with greater value in mind.
Enhanced flexibility in delivery, increased investment in digital capability, and quick adaptation to events were some of the positive impacts of the COVID-19 pandemic on cancer care.
At the 11th Annual Summit of the Association for Value-Based Cancer Care (AVBCC) in 2021, health plans and employers discussed the utility of value-based contracting for managing oncology care costs while maintaining focus on outcomes of value for patients.
Total growth in the oncology pipeline in 2020 has been driven by targeted therapies, said Doug Long, Vice President, Industry Relations, IQVIA, at the 10th Annual Summit of the Association for Value-Based Cancer Care (AVBCC) in 2020.
n an environment of increasing vertical and horizontal integration in healthcare, are new value-based care models in oncology—such as the Centers for Medicare & Medicaid Services’ pilot payment project, the Oncology Care Model (OCM)—working? Five years from now, will we still be talking about efforts to go from volume to value using alternative payment models?
The COVID-19 pandemic has exposed many of the cracks in our healthcare system. According to Maurie Markman, MD, MS, FACP, FASCO, President, Medicine and Science, Cancer Treatment Centers of America, COVID-19 disproportionately affects the elderly, those with comorbidities, and racial and ethnic minority populations, all of whom are more likely to have serious or fatal illness.

Results 1 - 7 of 7